Search clinical trials for: Glargin

Total 615 results

ikfe-CRO GmbH
Sanofi; IKFE Institute for Clinical Research and Development

Completed

Beta Cell Relieving and Cardiovascular Protective Effects of LANTUS Treatment in Type 2 Diabetes Patients

Diabetes Mellitus, Type 2

Germany
Eli Lilly and Company

Completed

A Study for Type 2 Diabetic Patients

Type 2 Diabetes Mellitus

Brazil, Canada, Mexico, India, Australia, China, Korea, Republic of
Sanofi

Completed

DOMME Dose Optimization Multicentric Mexican Evaluation (DOMME)

Diabetes Mellitus, Type 2

Mexico
Sanofi

Completed

Insulin Analogue With Continuous Glucose Monitoring System (CGMS) Measurement (SAFIR)

Diabetes Mellitus Type 2
Sanofi

Completed

Insulin Glargine in Type I Diabetes Mellitus> Main Study "AT.LANTUS": A Trial Comparing Lantus Algorithms to Achieve Normal Blood Glucose Targets in Subjects With Uncontrolled Blood Sugar. Sub-study: "HALT"(Hypoglycaemia Avoidance With Lantus Trial) (AT-LANTUS)

Diabetes Mellitus, Type 1
Sanofi

Completed

A Trial Comparing Lantus Algorithms to Achieve Normal Blood Glucose Targets in Subjects With Uncontrolled Blood Sugar With Type 2 Diabetes Mellitus (AT-LANTUS)

Diabetes Mellitus, Type 2
University of Padova

Completed

Endothelial Effects of Basal Insulin: Detemir Versus Glargine

Cardiovascular Disease | Type 2 Diabetes | Endothelial Dysfunction

Italy
Sanofi

Completed

Comparison Safety and Efficacy of Basal Insulin Lantus® (Insulin Glargine) vs NPH Insulin in Combination With Oral Antidiabetic Drugs (OADs) in Patients With Diabetes Mellitus, Type 2 (DMT2) (COBIN 2)

Diabetes Mellitus, Type 2

Czech Republic
Population Health Research Institute

Completed

REsearching Coronary REduction by Appropriately Targeting Euglycemia (RECREATE Pilot Study) (RECREATE Pilot)

Hyperglycemia | Myocardial Infarction | Cardiovascular Diseases

Argentina, Canada, India
Cairo University
Sanofi

Unknown

Various Insulin Regimens for Diabetic Inpatients With Cirrhosis Trial (VIRDICT)

Liver Cirrhosis | Type 2 Diabetes

Egypt
Sanofi

Terminated

Type 2 Diabetes Management With Lantus® (Malbec: Manejo Con Lantus® de Diabéticos Tipo 2) (Malbec)

Type 2 Diabetes

Argentina
Diabetes Care Center

Unknown

A Study of the Rules for Insulin Dosing in Patients Using Multiple Daily Injections

Diabetes Mellitus Type 1

United States
Munich Municipal Hospital
Aventis Pharmaceuticals

Unknown

Can Insulin Glargine Improve Myocardial Function in Patients With T2D and Coronary Artery Disease (CAD)

Coronary Artery Disease | Type 2 Diabetes

Germany
Eli Lilly and Company

Completed

Comparison of Two Approaches to Insulin Therapy in Patients With Type 2 Diabetes (IOOX) (IOOX)

Diabetes Mellitus, Type 2

Australia, Russian Federation, Spain, Mexico, Canada, France, Korea, Republic of
Sanofi

Completed

Evaluate Quality of Life in Type 2 Diabetes, Before and After Change to Insuline Glargine (QoL)

Diabetes Type 2

Sweden
Sanofi

Terminated

LANTUSTITR: Insulin Glargine in Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

Hungary
Sanofi

Completed

ELEONOR STUDY: Insulin Glulisine in Type 2 Diabetes Mellitus.

Diabetes Mellitus, Type 2

Italy
Sanofi

Completed

Efficacy Study on the Control of Blood Glucose Concentration in Type 1 Diabetic Patients (VARIABILITE)

Diabetes Mellitus, Type 1

France
Sanofi

Completed

Lantus Effect on Myocardial Glucose Metabolism in T2

Diabetes Mellitus, Type 2

Italy
Sanofi

Completed

Insulin Glargine in Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2
Sanofi

Completed

SAM - Skip a Meal - Insulin Glargine, Diabetes Mellitus Type 1

Diabetes Mellitus, Type 1

Germany
Mannkind Corporation

Completed

A 3 Month, Randomized, Open Label, Multi-center Study of Technosphere/Insulin Compared to Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Receiving Insulin Glargine

Diabetes Mellitus, Type 1
Sanofi

Completed

Insulin Glargine Combination Therapies in Type II Diabetics (LAPTOP)

Diabetes Mellitus, Type 2

France, Germany, Netherlands, Spain, Sweden, Switzerland, United Kingdom, Finland, Italy, Austria
Sanofi

Completed

Gulf, Lantus, Apidra Evaluation in Type 1 Diabetics Study (GLANS)

Diabetes Mellitus, Type 1

Bahrain, Kuwait, Qatar, United Arab Emirates
Sanofi

Completed

Insulin Glargine in Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus
Sanofi

Completed

Insulin Glulisine in Diabetes Mellitus, Type 2 (GINGER)

Diabetes Mellitus, Type 2

France, Spain, Italy, Belgium, Germany, Poland, Portugal, Czech Republic, Slovakia, Australia, Netherlands, Sweden, United Kingdom, Switzerland, Romania
Sanofi

Completed

Opposing Step-by-step Insulin Reinforcement to Intensified Strategy (OSIRIS)

Diabetes Mellitus, Type 2

France, Korea, Republic of, Russian Federation, Spain, Italy, Belgium, Germany, Hungary, Ireland, Mexico, Poland, Taiwan, Turkey, Netherlands, Greece, Lithuania, Sweden, United Kingdom
Sanofi

Completed

Insulin Glulisine, Insulin Lispro and Insulin Glargine in Type 1 or 2 Diabetes Mellitus

Diabetes Mellitus

China
Sanofi

Completed

Insulin Glargine in Type 2 Diabetic Patients (TARGET)

Diabetes Mellitus, Type 2

China
Sanofi

Completed

Lantus Versus Levemir Treat-To-Target (L2T3)

Diabetes Mellitus, Type 2

Korea, Republic of, Russian Federation, Spain, Denmark, Canada, Germany, Ireland, Portugal, Australia, India, Turkey, Netherlands, Sweden, United Kingdom, Finland, Switzerland, Romania, Brazil, Serbia, Taiwan
John H. Stroger Hospital
Eli Lilly and Company

Completed

Insulin Therapy in the Hospital Comparing Two Protocols

Diabetes Mellitus, Type 2

United States
Profil Institut für Stoffwechselforschung GmbH
Sanofi

Completed

Adjunctive Therapy of Exenatide or Sitagliptin to Insulin Glargine in Type 2 Diabetes

Type 2 Diabetes

Germany
Hallym University Medical Center

Completed

Insulin Dose Titration System Using a Short Messaging Service (SMS) Automatically Produced by a Knowledge Matrix

Diabetes Mellitus, Type 2
Sanofi

Completed

Glycemic Optimization Treatment Study (GOT)

Diabetes Mellitus, Type 2
ikfe-CRO GmbH
IKFE Institute for Clinical Research and Development

Completed

Beta-Cell Function of Insulin Glargine Compared to Neutral Protamine Hagedorn (NPH) Insuline and to Insulin Detemir in Combination With Metformin

Type 2 Diabetic Patients | Insufficient Metabolic Control | OAD Treatment

Germany
Sanofi

Completed

LAPAS Study: Insulin Glargine in Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

Israel
Sanofi

Completed

Insulin Glargine Plus Insulin Glulisine Multiple Daily Injections (MDI) Versus Premix Insulin Treatment in Subjects With Diabetes Mellitus (Type 1 or Type 2)

Diabetes Mellitus

United States
Sanofi

Completed

Effect of Insulin Glargine in Insulin Naïve Subjects With Type 2 Diabetes on Oral Hypoglycemic Agent(s)

Diabetes Mellitus, Type 2

United States, Canada
Northwestern University
Sanofi

Completed

Conversion of Hyperglycemic Patients Being Treated With Intravenous Insulin Infusions to Lantus Insulin

Hyperglycemia | Diabetes

United States
Sanofi

Completed

Comparison of Insulin Glargine and NPH Human Insulin in Progression of Diabetic Retinopathy in Type 2 Diabetic Patients

Diabetes Mellitus, Type 2

United States, Canada
Heidelberg University

Unknown

Prospective Influence of Bedtime Insulin Glargine on Mobilization and Function of Endothelial Progenitor Cells

Type 2 Diabetes

Germany
Sanofi

Completed

Phenotype Evaluation in Insulin Naive Patients Using Lantus (Insulin Glargine) (GALATEE)

Type 2 Diabetes

France
Sanofi

Completed

Insulin Glargine Benefits in Japanese Pts Outside of Japan (US or Brazil)

Diabetes Mellitus

Brazil
Sanofi

Completed

Insulin Glargine, INITIATE Metabolic and Economic Outcomes of Lantus

Diabetes Mellitus

Sweden, Finland, Netherlands, United Kingdom
John H. Stroger Hospital

Completed

Combination of Sulfonylureas and Insulin Glargine Outpatient Therapy for Unstable Diabetes and Impending DKA

Type 2 Diabetes

United States
University of Campania "Luigi Vanvitelli"

Completed

Bedtime Insulins and Oral Antihyperglycemic Drugs in Type 2 Diabetes

Hypoglycemia | Type 2 Diabetes Mellitus

Italy
Sanofi

Completed

The Incidence of Hypoglycemia in Insulin Glargine-Treated Subjects With Diabetes Mellitus Upon Switching Between Bedtime and Morning Dosing

Diabetes Mellitus

Mexico
Skane University Hospital
Medical Research Council; Skane County Council Research & Development Foundation

Completed

Pioglitazone vs. Insulin Glargine in the Treatment of Secondary Drug Failure in Type 2 Diabetes

Type 2 Diabetes | Secondary Drug Failure

Sweden
Pfizer

Completed

A Clinical Trial Comparing Short-Term Efficacy and Safety of Exubera and Lantus

Diabetes Mellitus, Type 2

United States
Sanofi

Completed

Extension to Study HMR1964A/3011 in Belgium

Diabetes Mellitus

Belgium

3

Subscribe